Topic
Topic
Dermatology Times reports that adding tirzepatide to ixekizumab shifted biomarkers in adults with plaque psoriasis and obesity, reframing two years of dermatology-endocrinology conference conversatio…
Lilly reports Zepbound (tirzepatide) enhanced Taltz (ixekizumab) efficacy in a psoriasis study, a signal for combination therapy…
Eli Lilly says a psoriasis study found Taltz plus Zepbound outperformed Taltz monotherapy; full efficacy and safety data are stil…
Dermatology Times: ixekizumab plus tirzepatide shifted biomarkers in psoriasis patients with obesity. Detailed PASI, inflammatory…
Italian centers publish a multicentric retrospective observational study of ixekizumab in psoriatic arthritis, adding real-world…
